Introduction
Johnson&Johnson Sıhhi Malzeme Sanayi ve Ticaret Ltd.
Şti.
("Johnson&Johnson") applied
in June 2019 to the Turkish Competition Authority
("TCA") and asked the
Competition Board ("Board") to
assess whether Johnson&Johnson's contemplated Warehouse
Sale Agreement for Human Medicine
("Agreement") falls within the
protective cloak of the Block Exemption Communiqué No.
2002/2 on Vertical Agreements ("Communiqué
No. 2002/2") or, if not, satisfies the
conditions for an individual exemption as per Article 5 of the Law
No. 4054 on the Protection of the Competition
("Law No. 4054").
The Agreement sought to establish a quantitative1
selective distribution system whereby nine pharmaceutical
warehouses that satisfy certain criteria determined by
Johnson&Johnson would be appointed as the authorized
distributors of four pharmaceuticals (Imbruvica, Zytiga, Stelara
and Darzalex) to pharmacies ("Proposed
Distribution System"). Johnson&Johnson would
not be under